Circulating extracellular vesicle-enriched fraction in heart failure with reduced ejection fraction and incident cancer
European Heart Journal Open · 2026-11-03 · 6 (6)
DOI: 10.1093/ehjopen/oeag180 ↗Abstract
Abstract Aims Previous studies found increased cancer incidence in patients with heart failure with reduced ejection fraction (HFrEF). We sought to explore the biological correlates of the association of HFrEF with cancer in humans. Methods and results Among participants in the Gruppo Italiano per lo Studio della Sopravvivenza nell’Insufficienza Cardiaca—Heart Failure (GISSI-HF) trial with HFrEF and available baseline plasma samples, we selected those who developed solid cancer (cases) and matched them with controls without cancer by age, sex, New York Heart Association class, and follow-up duration. We isolated the plasma extracellular vesicle (EV)-enriched fraction, in which EVs were confirmed by western blot for CD9, FLOTILLIN-1, ALIX, and TSG101, and by nanoparticle tracking analysis (mean particle diameter <200 nm). The protein content of EV preparations was characterized by nanoliquid chromatography-high=resolution tandem mass spectrometry. Of the 940 identified proteins, 148 were differentially expressed between EV preparations from cases (EVs-cases) and controls (EVs-controls) and were related to biological functions implicated in cancer growth, particularly apoptosis and spliceosome/transcriptome regulation. Next, we explored the effects of EVs-cases and EVs-controls in MCF7 breast cancer cells and ran confirmatory experiments with another two cell lines, HCT116 (colon) and A549 (lung). Apoptosis, as determined by caspase 3 cleavage, was blunted by EVs-cases in MCF7, but not in HCT116 and A549 cells. Screening qPCR identified NR3C1, encoding the glucocorticoid receptor, as a spliceosome/transcription modulator affected by EVs-cases. Targeted qPCR confirmed that it was reduced by EVs-cases in A549 cells. Conclusion Circulating EV-enriched fractions from patients with HFrEF and incident cancer have a distinct proteomic signature and might modulate human cancer cell biology.
EUVIMED